From Wikipedia, the free encyclopedia
Chemical compound
Galunisertib
Routes of administration PO
4-(5,6-Dihydro-2-(6-methyl-2-pyridinyl)-4H -pyrrolo(1,2-b)pyrazol-3-yl)-6-quinolinecarboxamide
CAS Number
PubChem
CID
ChemSpider
UNII
KEGG
ChEBI
CompTox Dashboard (
EPA )
Formula C 22 H 19 N 5 O
Molar mass 369.428 g·mol−1 3D model (
JSmol )
N1=CC=C(C2=CC(=CC=C12)C(=O)N)C1=C2N(N=C1C1C=CC=C(N=1)C)CCC2
InChI=1S/C22H19N5O/c1-13-4-2-5-18(25-13)21-20(19-6-3-11-27(19)26-21)15-9-10-24-17-8-7-14(22(23)28)12-16(15)17/h2,4-5,7-10,12H,3,6,11H2,1H3,(H2,23,28)
Key:IVRXNBXKWIJUQB-UHFFFAOYSA-N
Galunisertib (LY2157299) is a small molecular experimental cancer drug previously in development by
Eli Lilly . It is a
TGF-b inhibitor.
[1] Development of galunisertib by Eli Lilly was discontinued in January 2020.
[2]
Galunisertib was investigated in a phase II trial for treatment of
hepatocellular carcinoma .
[3] Pre-clinically, combination of galunisertib with
PD-L1 blockade resulted in improved tumor growth inhibition.
[4]
References
^
"Lilly Oncology Pipeline - Lilly USA" . www.lillyoncologypipeline.com .
^
"Eli Lilly cuts 3 cancer drugs amid Q4 clear-out" .
^ Clinical trial number
NCT01246986 for "A Study of LY2157299 in Participants With Hepatocellular Carcinoma" at
ClinicalTrials.gov
^ Holmgaard RB, Schaer DA, Li Y, Castaneda SP, Murphy MY, Xu X, Inigo I, Dobkin J, Manro JR, Iversen PW, Surguladze D, Hall GE, Novosiadly RD, Benhadji KA, Plowman GD, Kalos M, Driscoll KE (June 2018).
"Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade" . Journal for Immunotherapy of Cancer . 6 (1): 47.
doi :
10.1186/s40425-018-0356-4 .
PMC
5987416 .
PMID
29866156 .